Erin Mulvey

Assistant Professor @WeillCornell Hematology/Oncology @NYPHospital specializing in lymphoma and CLL

[Ajay Major, MD, MBA @majorajay]

Sequencing of CAR v BsAb LBCL (ABC Consortium) #ASH25
- 230 pts, glofi most common
- no diff PFS or OS between CAR▶️BsAb vs BsAb first
- no diff PFS or OS between BsAb▶️CAR vs CAR (except primary refractory, in which OS advantage to CAR before BsAb)
Timely study. #lymsm #tcellrx

[Ajay Major, MD, MBA @majorajay]

Symptom-based PFS CLL/SLL #ASH25
- 606 pts in ALPINE (zanu v ibru)
- longitudinal fatigue, insomnia, N/V associated with increased risk of PD (regardless of BTKi)
- zanu: lower odds of symptom worsening vs ibrutinib
More trial data demonstrating prognostic value of PROs! #leusm

[Erin Mulvey @ECMulvey]

It’s here!!

[John P. Leonard, MD @JohnPLeonardMD]

Here is #LeonardList 10 in countdown of #ASH2025 #ASH25 top #lymphoma abstracts - Passerini et al abst 25 : EZH2 and CREBBP mutation status identify pts who benefit from bendamustine over CHOP/CVP-based immunochemotherapies in follicular lymphoma https://t.co/tH8djADlN1

[Erin Mulvey @ECMulvey]

Looking forward to this Ajay!

[Ajay Major, MD, MBA @majorajay]

Get stoked for this year’s #MajorPROsASH!
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ASH_hematology to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵#mmsm #leusm #lymsm

[Pinkal Desai @DrPinkalDesai]

Gail Roboz highlighting the importance of medical research and challenges of treating rare aggressive forms of leukemia @WCMLeukemia @CBSNews . For resilience of leukemia patients , their hopes and future, we need more research and investment in improving leukemia outcomes .

[Lymphoma Research Foundation @lymphoma]

On Nov. 18, the FDA announced it has approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL): https://t.co/MRePNOobR5

[Blood Journals Portfolio @BloodPortfolio]

EZH2 inhibition in B cells promotes AID-dependent chromosomal translocations in the presence of high AID activity or Ligase4 deficiency. https://t.co/CqSxg0lTP9 #lymphoidneoplasia

[Dr Rishabh Jain @DrRishabhOnco]

🚨 TIME TOXICITY in Cancer Care ⏰

How much of a patient’s remaining life is spent in hospitals instead of at home? 🏥💔

A first-of-its-kind prospective Indian study (CTRI/2023/05/053281) finds:

🧬 92 patients with advanced cancers
🕰️ Mean time toxicity = 226 hrs / 2 months (~9 days)
⚖️ 17% of life spent in healthcare-related activities
🚗 Travel & waiting time = 🔝 contributors
💉 Only ~1/8 of time adds real treatment value
💡 Higher QoL → lower time toxicity

🎯 Implication: For many with limited survival, time may be the most precious currency.
👉 Oncologists must weigh not only drug toxicity… but time toxicity.

📖 Mailankody et al., BMJ Supportive & Palliative Care, 2025

🔗https://t.co/ZsC5YNKWka

#PalliativeCare #OncoTwitter #MedTwitter #BMJ @OncoAlert @esmo_open @ASCO @myESMO @bmj_latest

[Carla Casulo, MD @DrCarlaCasulo]

Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? https://t.co/rFW0XwVqPT
Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer

[WCM Englander Institute for Precision Medicine @WCMEnglanderIPM]

Please join us in congratulating our Clinical Director Dr. Cora N. Sternberg (@cnsternberg) on being named to @guide2research's 2025 list of the Top 1000 Female Scientists!

She's ranked #305 in the U.S., and #516 in the world!

https://t.co/Wc1K0NejZC

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Honored to share our newly published manuscript https://t.co/xAH8RPTQNf which demonstrates that circulating tumor DNA (ctDNA) by PhasED-Seq offers the most precise definition of remission after frontline therapy for patients with large B-cell lymphoma (LBCL) out now in @JCO_ASCO. #ctDNA detection of #MRD. 1/18

[Toby Eyre @tobyeyre82]

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment https://t.co/YJ4RT2P9SG

[Lymphoma Hub @lymphomahub]

🚨NEWS 🚨
The @EU_Commission approves glofitamab, a T-cell-engaging bispecific antibody, in combination with gemcitabine and oxaliplatin for the treatment of adult patients with R/R DLBCL NOS who are ineligible for ASCT. This announcement is supported by the positive results from the phase III STARGLO trial.
Read more: https://t.co/0tDyIuPsFR
#lymphoma #lymsm #mednews

[Journal of Clinical Oncology @JCO_ASCO]

‼️ #ASCO25 simultaneous publication by @mshadman et al: 

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results: https://t.co/IPjjsIPg3W

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Implementation of Symptom Monitoring With Electronic Patient-Reported Outcomes: Perspectives and Recommendations From Community Oncology Practices (Alliance AFT-39).

https://t.co/UpfdTfA19J

@ASCO @JCO_ASCO @JCOOP_ASCO
#PallOnc #CancerCare
@ALLIANCE_org @EthanBasch1 @BiostatGirl

[Sam Yamshon @samyamshon]

We experience modern miracles daily and I constantly take a step back and marvel at:
- Videocalls with folks 1000s of miles away while walking on the street
- Ordering on my phone and things arrive the next day, free delivery
- Absolutely everything AI
https://t.co/JZr4EYPBXy

[Adam Kittai @AdamKittai]

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL | Blood Cancer Journal
https://t.co/R8gnvia3mc

[John P. Leonard, MD @JohnPLeonardMD]

Great collaboration with @ECMulvey @DrSarahruth The Future of Follicular Lymphoma Management: Strategies on the Horizon | Blood | American Society of Hematology https://t.co/AwPJk6cjDI

[Blood Journals Portfolio @BloodPortfolio]

The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy in TP53-mutant MCL. https://t.co/Wg5jZTmbE9 #clinicaltrialsandobservations #lymphoidneoplasia

[Kai Rejeski @KRejeski]

Great team science effort working together with @MSubklewe on this project!

Also important to highlight accumulating evidence on the importance of IR in CAR-T.

➡️ Check out the recent @MSKCancerCenter effort by @DannyLuan6 @RShouval et al in @BCD_AACR

https://t.co/IP60qb4lMn